Shanghai GeneChem Co., Ltd.
7
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
Role: lead
A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
Role: lead
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
Role: lead
A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
Role: collaborator
A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
Role: lead
A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
Role: lead
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
Role: lead
All 7 trials loaded